Drugs / VOB560
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04702425 | Jun 2021 → Jul 2024 | acute myeloid leukemia, non-Hodgkin lymphoma, plasma cell myeloma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT03755154 | Jul 2019 → Nov 2023 | B-cell chronic lymphocytic leukemia, acute myeloid leukemia, refractory plasma cell neoplasm | Servier | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04742101 | Mar 2021 → Mar 2026 | acute myeloid leukemia | Servier | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VOB560 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04702425 ↗ |
| Known as | S65487 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03755154 ↗ |
| Action | Inhibit | “a Bcl-2 Inhibitor” NCT03755154 ↗ |
| Modality | Small molecule | — CHEMBL3701382 ↗ |
| Route | Intravenous | “administered intravenously” NCT03755154 ↗ |
| Target | BCL2 | “S65487, a Bcl-2 Inhibitor” NCT03755154 ↗ |